Key Features

Different doses of Dapoforce

• Dapoforce 30 mg
• Dapoforce 60 mg
• Dapoforce 90 mg

 Features of Dapoforce Medication

• Medications like Dapoforce 30 mg, Dapoforce 60 mg, and Dapoforce 90 mg contains Dapoxetine Hydrochloride as an active ingredient.
• These medications are being used to treat Premature Ejaculation (PE).
• These medications have similar mechanism of action.
• These typically takes 60-180 minutes after oral administration.

How does Dapoforce work? 

Dapoxetine functions by raising the levels of serotonin in the brain, specifically in those regions that are accountable for ejaculation. This delays ejaculation and enhances control so that sexual intercourse can be more enjoyable. 

• Dapoxetine is a type of drug known as selective serotonin reuptake inhibitors (SSRIs).
• It raises the level of serotonin in the nervous system, thereby delaying ejaculation and enhancing ejaculation control.

Ejaculatory Latency Control 

Dapoforce dapoxetine increases ejaculatory latency control for premature ejaculation by raising the intravaginal ejaculatory latency time (IELT). Research has indicated that dapoxetine can Lengthen IELT, Dapoxetine has been found to prolong IELT by 3-4 times over placebo, with excellent improvements in ejaculatory control and sexual satisfaction.

Uses

• Men’s premature ejaculation treatment
• Control of ejaculation
• Sexual satisfaction

Dosage

• Starting dose of Dapoforce is 30 mg and can be extended up to 60-90 mg depending on the requirement within an interval of 24 hours.
• It can be taken 1-3 hours before sexual activity.

Different doses of Dapoforce

• Dapoforce 30 mg
• Dapoforce 60 mg
• Dapoforce 90 mg

Side Effects 

• Nausea
• Dizziness
• Headaches
• Diarrhea
• Difficulty sleeping
• Serotonin syndrome

Interactions 

• Serotonergic drugs: Dapoforce if taken with other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors (MAOIs), can elevate the risk of serotonin syndrome.
• PDE5 inhibitors: While Dapoforce does not have PDE5 inhibitors, co-administration of Dapoforce with PDE5 inhibitors can enhance the risk of orthostatic hypotension.
• CYP2D6 or CYP3A4 inhibitors: Dapoforce is metabolized by liver enzymes CYP2D6 and CYP3A4. Concomitant administration of drugs that inhibit these enzymes can lead to increased body concentrations of Dapoforce and potentially enhance the risk of side effects.
• Other drugs: Dapoforce can interact with other drugs, including thioridazine, and make it more likely to have side effects.

Pharmacokinetics 

• Dapoxetine is absorbed rapidly, reaching peak plasma concentrations within about 1 hour after dosage.
• It exhibits a biphasic elimination profile with an initial half-life of 1.4 hr and a terminal elimination half-life of 20 hr.
• Dapoxetine is metabolized in the liver and then excreted mainly via the kidneys.

Clinical Efficiency in Trials 

• Dapoxetine showed a statistically significant improvement in intravaginal ejaculatory latency time and PROs compared with placebo.
• Pooled analysis of five phase 3 trials showed that Dapoxetine 30mg and 60mg significantly increased IELT and improved PROs with a statistically significant difference from placebo.
• Adverse events (most common) included nausea, dizziness, headache, and diarrhea.

Precautions 

• Consult a medical professional or a doctor prior having such medications.
• Inform your healthcare provider about any medical prior history, or medical condition or allergies.
• Dapoforce is not for men younger than 18 years and older than 65 years.

Conclusion 

Dapoforce is safe and effective for treating premature ejaculation, fast-acting, and slightly accumulative. Clinical trials confirm its efficacy in improving IELT and PROs, it acts as an SSRI. This means that it promotes an increased amount of serotonin in the brain and helps to delay in ejaculation. It is recommended to consult a medical professional prior using any medication.

References

https://pubmed.ncbi.nlm.nih.gov/27456527/

https://pubmed.ncbi.nlm.nih.gov/32172793/